Key result
Adjuvant pazopanib yields ~5 years of tumor control in an EWSR1-NFATC2 positive bone sarcoma case.
Case Report (n=1)
Pazopanib combined with surgery may provide long-term tumor control in patients with EWSR1-NFATC2 translocation-associated bone sarcoma.
Answers are grounded in this paper and cite their sources.
May warrant consideration in rare EWSR1-NFATC2 sarcomas; hypothesis-generating and requires prospective validation before practice change.
Pazopanib is a multi-kinase inhibitor that is currently approved for treatment of advanced renal cell carcinoma and chemotherapy-refractory soft tissue sarcoma.In this case report, we discuss the case of a patient with a EWSR1-NFATC2 fusion positive bone sarcoma who had exceptional tumor control through using pazopanib and surgery for an overall duration exceeding 5 years.We also review the literature on EWSR1-NFATC2 translocation-associated sarcomas and use of pazopanib in bone sarcomas.
No takes yet. Share an insight, caveat, or question.
Gouda et al. (2023) conducted a case report in EWSR1-NFATC2 fusion positive bone sarcoma (n=1). Pazopanib was evaluated on Disease control duration. Pazopanib administered as an adjuvant therapy provided exceptional tumor control for over 5 years in a patient with EWSR1-NFATC2 fusion positive bone sarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: